MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 3,216 Shares of Danaher Corporation $DHR

Key Points

• MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Danaher Corporation by 5.1%, acquiring an additional 3,216 shares to bring its total holdings to 66,750 shares, valued at approximately $13.7 million.
• Danaher reported quarterly earnings of $1.80 per share, surpassing analysts' estimates and showing an increase in revenue to $5.94 billion compared to the previous year's quarter.
• The company has announced a quarterly dividend of $0.32 per share, with a dividend yield of 0.7% and a payout ratio of 27.23%.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 5.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 66,750 shares of the conglomerate's stock after buying an additional 3,216 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Danaher were worth $13,684,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Bank Pictet & Cie Europe AG raised its position in shares of Danaher by 22.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate's stock worth $44,241,000 after acquiring an additional 35,730 shares during the last quarter. Minot DeBlois Advisors LLC bought a new stake in Danaher during the 4th quarter worth about $1,606,000. Obermeyer Wealth Partners raised its holdings in Danaher by 25.6% during the 4th quarter. Obermeyer Wealth Partners now owns 2,012 shares of the conglomerate's stock worth $462,000 after purchasing an additional 410 shares during the last quarter. OMERS ADMINISTRATION Corp raised its holdings in Danaher by 74.3% during the 4th quarter. OMERS ADMINISTRATION Corp now owns 50,202 shares of the conglomerate's stock worth $11,524,000 after purchasing an additional 21,397 shares during the last quarter. Finally, Numerai GP LLC bought a new stake in shares of Danaher during the fourth quarter worth approximately $1,983,000. 79.05% of the stock is owned by institutional investors.

Danaher Trading Up 1.4%

Shares of DHR traded up $2.64 during trading hours on Thursday, reaching $195.23. The stock had a trading volume of 3,425,999 shares, compared to its average volume of 3,039,142. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.90. The firm has a 50-day moving average of $201.62 and a 200 day moving average of $199.15. The company has a market cap of $139.79 billion, a P/E ratio of 41.54, a P/E/G ratio of 2.69 and a beta of 0.75. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same period in the prior year, the company earned $1.72 earnings per share. The company's revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.7%. Danaher's dividend payout ratio is currently 27.23%.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on DHR. Guggenheim reissued a "buy" rating and set a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective for the company in a report on Friday, July 11th. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Finally, Barclays reiterated an "overweight" rating and issued a $225.00 price objective (up previously from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Seventeen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $246.35.

Insider Activity

In other Danaher news, Director Teri List sold 2,778 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 11.10% of the stock is owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.